Immunic, inc. strengthens its board of directors with the appointment of experienced pharmaceutical executive simona skerjanec

– senior executive and thought leader in brain health with nearly three decades of global pharmaceutical experience – – served as neuroimmunology franchise head responsible for roche's blockbuster launch of multiple sclerosis therapy ocrevus® – new york , july 24, 2024 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of simona skerjanec, m.pharm, mba, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective july 22, 2024. over a nearly three-decade career in the united states and internationally, ms.
IMUX Ratings Summary
IMUX Quant Ranking